Trump’s statements sure to increase demand for COVID-19 mAbs

Just hours after Eli Lilly became the first COVID-19 mAb developer to disclose it had requested emergency use authorization, President Donald Trump released a video calling for immediate authorization of both Lilly’s and Regeneron’s mAbs, and asserted the therapies would be available free of charge. 

The day ended with a statement from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) that it has submitted a request for EUA of its mAb cocktail REGN-COV2 that was used in Trump’s treatment last week...